Skip to main content
editor.ajphr@gmail.com
9409046853
e-ISSN: 2321-3647
American Journal of Pharmacy and Health Research

American Journal of Pharmacy and Health Research

Keyword

diabetic nephropathy

Explore 1 research publication tagged with this keyword

1Publications
1Authors
1Years

Publications Tagged with "diabetic nephropathy"

1 publication found

2026

1 publication

Molecular Mechanisms In the Pathogenesis of Diabetic Nephropathy: Historical Development, Intracellular Signalling Pathways, Molecular Targets and Contemporary Therapeutic Strategies

Devansh Mehta
11/16/2026
pp. 43-73

Diabetic nephropathy (DN), increasingly described within the broader clinical framework of diabetic kidney disease (DKD), represents a major microvascular complication of diabetes mellitus and a leading contributor to chronic kidney disease and end-stage kidney failure worldwide. Its pathogenesis involves complex interactions among chronic hyperglycaemia, haemodynamic abnormalities, oxidative stress, inflammatory mediators, mitochondrial dysfunction, endothelial injury, podocyte damage and progressive extracellular matrix accumulation. Historically, the understanding of DN has evolved from morphological descriptions of glomerulosclerosis to the identification of hyperfiltration, renin–angiotensin–aldosterone system activation and multiple intracellular signalling networks. This review examines the historical development and molecular basis of DN, emphasising advanced glycation end-products and receptor for advanced glycation end-products signalling, protein kinase C activation, polyol and hexosamine pathways, transforming growth factor-β/Smad signalling, nuclear factor-κB, mitogen-activated protein kinases, phosphatidylinositol-3-kinase/Akt/mTOR, AMP-activated protein kinase, Nrf2/Keap1, Wnt/β-catenin and NLRP3 inflammasome activation. Particular attention is given to podocyte dysfunction, glomerular endothelial abnormalities, tubular metabolic stress, epigenetic regulation and renal fibrosis. Contemporary therapeutic strategies, including renin–angiotensin system inhibitors, sodium–glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists, are evaluated alongside landmark clinical trials and emerging molecular interventions. The review also discusses integrated treatment approaches, biomarker-based risk stratification and future therapeutic directions. Understanding the convergence of metabolic, haemodynamic and inflammatory pathways is essential for developing individualised, evidence-based interventions capable of delaying renal disease progression and improving long-term cardiorenal outcomes.

Keyword Statistics
Total Publications:1
Years Active:1
Latest Publication:2026
Contributing Authors:1
Whatsapp